Kronisk bronkitis/ Rygerlunger Clinical Trials
A listing of Kronisk bronkitis/ Rygerlunger medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 109 clinical trials
Sarcopenia, Fall and Osteoporosis in Chronic Kidney Disease
This study is a cross-sectional study that wishes to investigate whether there is an increased incidence of sarcopenia in patients with chronic kidney disease compared to the Danish background population. A possible association between sarcopenia and fall, as well as the incidence of osteoporosis in patients with chronic kidney disease …
Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis
The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.
Primary Care Management of Osteoporosis in Older Women
The Investigators aim to improve primary-care for older women with osteoporosis. Older women they spoke with previously felt unseen, unimportant, unheard and uninformed. These women felt that bone/joint health was an important issue for women aged 70+. Osteoporosis is a disease that makes bones more breakable and can lead to …
New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic …
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
Teriparatide (PTH) is the only bone formation therapy that has been approved for the treatment of postmenopausal osteoporosis in Canada. Osteoporosis is currently diagnosed using a bone mineral density (BMD) scan, which measures the amount of mineral (calcium etc) in bones (the higher the amount of mineral, the lower the …
Health Literacy's Impact on Exercise Habits and Medication Adherence in Postmenopausal Osteoporosis
Postmenopausal osteoporosis is characterized by low bone mass and increased fracture risk. Treatment includes exercise, nutrition, supplements, and medications like bisphosphonates, denosumab, or hormone replacement therapy. Lifestyle changes such as quitting smoking, reducing alcohol consumption, and preventing falls are also crucial. Despite effective treatments, adherence is low: 20-30% of patients …
Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures
Osteoporosis (OP) is one of most common age-associated and chronic metabolic bone diseases, featured by a decrease of bone mineral density (BMD) that increases the risk of bone fractures.OP guidelines agree that Dual-X-ray Absorptiometry (DXA) is the gold standard for BMD assessment, but for the different OP stages screening and …
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis. The study will consist of a single visit that will coincide with one of the patient's usual follow-up visits according …
Sequential Therapies After Osteoanabolic Treatment
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
